Personalised medicine in the context of drug development

V-Learning: Dr Tobias Arkenau discusses the complexity of oncology drug development in the era of personalised medicine. It is expected from tailored treatment to reduce “trial-and-error” medicine, make the use of drugs safer by reducing adverse side effects, develop strategies, including novel trial designs, for reducing the time and cost of drug development, and allow use of surrogate endpoints in proof-of-concept trials.

This video is part of an ESMO V-learning module on personalised medicine and can be accessed via OncologyPRO:

Video produced by the European Society for Medical Oncology (ESMO)